May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
51 citations
,
January 2024 in “Nanoscale” Nano-PROTACs could improve drug targeting and delivery by using nanotechnology.
6 citations
,
February 2025 in “Scientific Reports” MEGA PROTAC improves prediction and ranking of protein complexes better than existing methods.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
November 2025 in “Journal of Medicinal Chemistry” Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
March 2026 in “Bioconjugate Chemistry” Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.
7 citations
,
January 2023 in “Journal of Hematology & Oncology” Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
4 citations
,
June 2025 in “MedComm” PROTACs show promise for cancer treatment, but designing them effectively is challenging.
18 citations
,
October 2018 in “Journal of The American Academy of Dermatology” Some skin medications can harm male fertility, but they don't seem to cause birth defects from father's exposure.
2 citations
,
January 2023 in “International journal of biological sciences” Gray hair can potentially be reversed, leading to new treatments.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
6 citations
,
June 2025 in “Nano Biomedicine and Engineering” Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.
August 2024 in “Asian Journal of Research in Chemistry” Repurposing existing drugs can improve cancer treatment but faces challenges.
April 2018 in “Journal of Investigative Dermatology” CREB, a protein that can promote cancer traits, is controlled by β-catenin in skin cancer cells.
72 citations
,
January 2003 in “American Journal of Pathology” A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.
36 citations
,
September 1999 in “Journal of Cell Science” Basonuclin may help control ribosomal RNA gene activity in skin cells.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
1 citations
,
January 2012 The CRABP I gene in cashmere goats is highly conserved but has unique features at specific amino sites.
3 citations
,
February 2018 in “Experimental and Molecular Medicine/Experimental and molecular medicine” A protein called PCBP2 controls the production of a hair growth protein by interacting with its genetic message and is linked to hair loss when this control is disrupted.
April 2019 in “Journal of Investigative Dermatology” Non-coding RNA boosts retinoic acid production and signaling, aiding regeneration.
62 citations
,
January 2009 in “Biochemistry” Vitamin D receptor binds similarly to natural and synthetic ligands, affecting gene regulation.
8 citations
,
June 2001 in “Journal of Biological Chemistry” A truncated protein linked to breast cancer may change cell adhesion.
84 citations
,
September 2008 in “Developmental biology” Retinoic acid-binding proteins in skin are regulated by β-catenin and Notch signalling.
4 citations
,
November 2024 in “Journal of Advanced Research” Targeting NMMHC IIA may help treat blood-brain barrier damage.
24 citations
,
July 2017 in “Structure” FGF9 controls which receptors it binds to through a process where two FGF9 molecules join, and changes in FGF9 can lead to incorrect receptor activation.
32 citations
,
July 2018 in “FEBS letters” A specific protein complex increases the activity of a plant enzyme, but this action is not required for plant root hair growth.